Alnylam Pharmaceuticals Q4 25 Earnings Conference Call At 8:30 AM ET

Alnylam Pharmaceuticals will host a conference call at 8:30 AM ET on February 12, 2026 to discuss fourth-quarter 2025 earnings, with a live webcast available at investors.alnylam.com/events. Hedge funds and equity investors should monitor the call for reported Q4 results and any management commentary or guidance revisions that could affect ALNY’s near-term fundamentals and share price.

Analysis

Contrarian angles: Consensus expects steady sales growth; what's missed is optionality from near-term label expansions or deals—market may underprice a successful regulatory/data nugget. Reaction risk: pre‑earnings selloffs often overshoot; a miss under −5% revenue could be a buying opportunity for a 6–12 month horizon if cash runway and pipeline milestones intact. Historical parallels: biotech events where guidance mattered more than EPS (e.g., enterprise biotech re‑rating episodes) suggest prioritize management commentary and 2026 revenue cadence over quarter-to-quarter EPS noise.

Key Decisions for Investors

• Establish a 2–3% long position in ALNY (ticker: ALNY) ahead of the Feb 12 call only if 30‑day implied vol <60%; implement via 30–60 day 10–15% OTM calls sized to 1–2% net portfolio risk, take profits on a >15% intraday rally, cut to zero on a >12% drop with negative guidance.
• If ALNY 2026 revenue guidance is trimmed by >5% vs consensus, initiate a 1–2% short position in ALNY (or buy equivalent‑delta 3‑month puts) targeting a 15–30% downside within 3 months; hedge with a small long position in IBB or XBI to limit sector contagion.
• Execute a pair trade: long ALNY equal‑dollar and short XBI (or another broad biotech ETF) equalized by 3‑month beta to isolate idiosyncratic ALNY upside; rebalance if spread widens by >10% or after major pipeline readouts.
• If pre‑call IV >80%, avoid buying volatility; instead sell a 45–60 day iron condor around implied move (collect premium targeting >0.6–0.9% theta of notional), and close within 5 trading days post‑earnings to avoid extended gamma risk.
• Accumulate a long-term 1–2% core position in ALNY on any post-call pullback >15% (from pre‑call price) provided cash runway >12 months and no material regulatory hits; reassess after quarterly guidance and next major pipeline milestone (6–12 months).